While effectively reducing drug prices and standardizing market order, the centralized volume-based procurement policy has also reshaped the market landscape, exerting a profound impact on the structure of industrial innovation dynamics. Against this backdrop, the emergence of the "developmental out-licensing" phenomenon in the innovative drug sector reflects both the deepening division of labor within China's pharmaceutical industry chain and the internationalization of asset flows. It also, to some extent, indicates a current gap in the capability and confidence of domestic enterprises to independently engage in global R&D and market competition. To guide the industry through this developmental bottleneck, safeguard the growth of domestic innovative capacity, and ultimately foster international competitiveness, it is particularly necessary to systematically study the shortcomings and optimization pathways of this model. Therefore, based on authoritative data and theoretical frameworks, and after analyzing its current status and characteristics, this paper aims to explore how to synergize efforts from the following four key dimensions: first, constructing a more sustainable financial support system; second, improving market return mechanisms that incentivize long-term innovation; third, cultivating an industrial ecosystem capable of supporting full-chain R&D; and fourth, strengthening policy coordination to guide industrial upgrading. This research seeks to provide solid systemic support through the aforementioned measures for the leapfrog development of China's innovative drug industry from "accessibility" to "controllability", and from "following" to "leading".